The Eaton Vance Worldwide Health Sciences Fund (Trades, Portfolio) sold shares of the following stocks during the fourth quarter.
Celgene
The fund exited its Celgene Corp. (CELG, Financial) position. The portfolio was impacted by -1.70%.
The biopharmaceutical company has a market cap of $77.04 billion and an enterprise value of $85.93 billion.
GuruFocus gives the company a profitability and growth rating of 9 out of 10. The return on equity of 71.15% and return on assets of 15.65% are outperforming 91% of companies in the drug manufacturers industry. Its financial strength is rated 5 out of 10. The cash-debt ratio of 0.55 is below the industry median of 0.93.
The largest guru shareholder of the company is Jim Simons (Trades, Portfolio)’ Renaissance Technologies with 2.18% of outstanding shares, followed by David Abrams (Trades, Portfolio) with 0.95% and John Paulson (Trades, Portfolio) with 0.45%.
Amgen
Eaton Vance reduced its Amgen Inc. (AMGN, Financial) holding by 52.04%. The portfolio was impacted by -1.32%.
The company, which produces biotechnology-based human therapeutics, has a market cap of $128.18 billion and an enterprise value of $149.17 billion
GuruFocus gives the company a profitability and growth rating of 10 out of 10. The return on equity of 71.65% and return on assets of 12.69% are outperforming 86% of companies in the drug manufacturers industry. Its financial strength is rated 4 out of 10. The cash-debt ratio of 0.3 is below the industry median of 0.93.
The largest guru shareholder of the company is PRIMECAP Management (Trades, Portfolio) with 3.06% of outstanding shares, followed by Simons’ firm with 0.62% and Richard Pzena (Trades, Portfolio) with 0.20%.
Novartis
The fund reduced its Novartis AG (NVS, Financial) position by 26.84%. The portfolio was impacted by -1.04%.
The pharmaceutical company has a market cap of $213.48 billion and an enterprise value of $231.54 billion.
GuruFocus gives the company a profitability and growth rating of 7 out of 10. The return on equity of 20.55% and return on assets of 9.24% are outperforming 79% of companies in the drug manufacturers industry. Its financial strength is rated 5 out of 10. The cash-debt ratio of 0.39 is below the industry median of 0.93.
The largest guru shareholder of the company is Dodge & Cox with 1.18% of outstanding shares, followed by PRIMECAP Management with 1.13% and Ken Fisher (Trades, Portfolio) with 0.37%.
Edwards Lifesciences
The fund trimmed its Edwards Lifesciences Corp. (EW, Financial) holding by 34.75%. The trade had an impact of -0.69% on the portfolio.
The company, which produces a range of medical devices and equipment, has a market cap of $45.87 billion and an enterprise value of $45.18 billion.
GuruFocus gives the company a profitability and growth rating of 10 out of 10. The return on equity of 29% and return on assets of 18.16% are outperforming 95% of companies in the medical devices and instruments industry. Its financial strength is rated 7 out of 10 with a cash-debt ratio of 2.24.
The company's largest guru shareholders include Frank Sands (Trades, Portfolio) with 3.55% of outstanding shares, Spiros Segalas (Trades, Portfolio) with 0.77% and Pioneer Investments (Trades, Portfolio) with 0.51%.
Amedisys
Eaton Vance divested of its Amedisys Inc. (AMED, Financial) position. The portfolio was impacted by -0.61%.
The American health care services company has a market cap of $5.78 billion and an enterprise value of $6.08 billion.
GuruFocus gives the company a profitability and growth rating of 6 out of 10. The return on equity of 24.26% and return on assets of 12.55% are outperforming 89% of companies in the healthcare providers and services industry. Its financial strength is rated 6 out of 10. The cash-debt ratio of 0.06 is far below the industry median of 0.54.
The largest guru shareholder of the company is Pioneer Investments with 0.37% of outstanding shares, followed by Lee Ainslie (Trades, Portfolio) with 0.11% and Joel Greenblatt (Trades, Portfolio) with 0.02%.
Agilent Technologies
The fund curbed its position in Agilent Technologies Inc. (A, Financial) by 34.75%. The portfolio was impacted by -0.46%.
The company has a market cap of $25.48 billion and an enterprise value of $26.51 billion.
GuruFocus gives the company a profitability and growth rating of 8 out of 10. The return on equity of 22.11% and return on assets of 12.01% are outperforming 86% of companies in the medical diagnostics and research industry. Its financial strength is rated 6 out of 10. The cash-debt ratio of 0.57 is below the industry median of 1.42.
The largest guru shareholder of the company is PRIMECAP Management with 1.43% of outstanding shares, followed by Bill Ackman (Trades, Portfolio) with 0.94% and Pioneer Investments with 0.55%.
Amplifon
The fund exited its holding of Amplifon SpA (MIL:AMP, Financial).The portfolio was impacted by -0.45%.
Vertex Pharmaceuticals
The fund curbed its position in Vertex Pharmaceuticals Inc. (VRTX, Financial) by 19.49%. The portfolio was impacted by -0.43%.
The company, which develops small-molecule drugs for the treatment of serious diseases, has a market cap of $59.28 billion and an enterprise value of $55.88 billion.
GuruFocus gives the company a profitability and growth rating of 4 out of 10. The return on equity of 23.01% and return on assets of 16.5% are outperforming 95% of companies in the biotechnology industry. Its financial strength is rated 8 out of 10 with a cash-debt ratio of 6.6.
Simons’ firm is the largest guru shareholder of the company with 2.26% of outstanding shares, followed by the Vanguard Health Care Fund (Trades, Portfolio) with 2.01% and Segalas with 0.79%.
Disclosure: I do not own any stocks mentioned.
Read more here:
- John Hussman Buys Amazon, Facebook
- 6 Outperforming Guru Stocks
- 6 Guru Stocks With Low Price-Earnings Ratios
Not a Premium Member of GuruFocus? Sign up for a free 7-day trial here.
